1,721,115 research outputs found
Attuali progressi nel trattamento dell’asma bronchiale nell’adulto
No full textNegli ultimi 20 anni ci sono stati miglioramenti sensazionali nel trattamento dell’asma bronchiale, dovuti in gran parte ad un uso più precoce e diffuso dei glucocorticoidi per via inalatoria che rimangono la classe di farmaci più importante per raggiungere il controllo ottimale della malattia. E’ probabile che, data la sua efficacia e sicurezza, l’attuale approccio farmacologico al trattamento dell’asma bronchiale continuerà anche per i prossimi 10 anni
Changing pharmacological approaches in mild asthma
No full textCurrent International and National guidelines on the management of asthma recommend a regular treatment with low doses of inhaled corticosteroids for patients with mild persistent asthma to achieve asthma control and reduce the risks of severe asthma exacerbations. However, recent clinical trials have hampered the traditional view that all patients with mild persistent asthma should be treated regularly with low doses of inhaled corticosteroids. Different strategies for the treatment of these patients have been recently proposed. Promising results have come from clinical trials that have tested different options, including the combination of inhaled corticosteroids and long-acting β2-agonists, oral leukotriene antagonist, and the intermittent or as-needed use of inhaled corticosteroids in the absence of regular treatment. Conversely, pharmacological approaches/strategies other than as-needed bronchodilation still need to be tested for the vast population of patients with mild intermittent asthma
Treatment of bronchial asthma in adults. Current advances
No full textThe last 20 years have shown an incredible improvement in the treatment of bronchial asthma, largely due to an earlier and more diffuse use of the inhaled glucocorticoids, that represent the pharmacological class of anti-asthma drugs more important to control the disease. Considering its efficacy and safety the current pharmacological treatment of asthma will probably remain unchanged for the next 10 years
Interactions of airway pathogens and inflammatory processes
No full textThe clinical history of chronic obstructive pulmonary disease (COPD) is punctuated by recurrent episodes of increases in dyspnea, cough, or sputum production named exacerbations. In addition to increasing COPD-associated morbidity and mortality, exacerbations contribute to loss of lung function and impaired health status in COPD patients (1)
Oxidants in asthma and in chronic obstructive pulmonary disease (COPD)
No full textExperimental and clinical evidences suggest that oxidants play a role in the pathogenesis of respiratory disorders characterised by chronic airway inflammation such as asthma and chronic obstructive pulmonary disease (COPD). The respiratory system is chronically exposed to environmental pollutants, including oxidants. Exogenous sources of oxidants are particularly relevant to the pathogenesis of COPD, being cigarette smoke an extremely rich source of oxidants. In addition, the inflammatory cells recruited to the airways of patients with asthma and COPD, have an exceptional capacity to produce oxidants. Many decades of research have produced a significant amount of data indicating pro-oxidative molecular mechanisms putatively relevant in the pathogenesis of the oxidative stress which characterises these diseases, both locally and systemically. As a consequence, a drug therapy able to restore the redox imbalance in asthma and COPD would probably exert clinical and functional benefits. Indeed, currently available therapies for asthma and COPD can exert an inhibitory effect on oxidant production in the airways. However, it is unknown whether the efficacy of the treatment is somehow linked to the pharmacological modulation of the oxidant/antioxidant balance. So far, it appears that the potential role of antioxidant compounds in the treatment of asthma and COPD has not been fully explored
- …
